No significant weaknesses identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MNKDMannKind Corporation | 1.73B | 5.64 | 58.02 | 43.5% | 9.32% | 1.89% | ||
| CORTCorcept Therapeutics Incorporated | 3.82B | 36.35 | 29.55 | 39.94% | 14.19% | 16.65% | 5.12% | 0.01 |
| GUTSFractyl Health, Inc. Common Stock | 308.28M | 2.01 | -1.24 | -22.5% | -40732.33% | -241.68% | 2.20 | |
| LXRXLexicon Pharmaceuticals, Inc. | 436.08M | 1.20 | -1.90 | 24.81% | -96.77% | -57.07% | 0.74 | |
| RZLTRezolute, Inc. | 229.96M | 2.48 | -2.53 | -52.45% | 0.01 | |||
| MISTMilestone Pharmaceuticals Inc. | 164.38M | 1.93 | -2.88 | -100% | -282.97% | 4.17 | ||
| ALTAltimmune, Inc. | 418.41M | 4.01 | -2.99 | -95.31% | -4195.75% | -45.21% | 0.01 | |
| BIOABioAge Labs, Inc. | 741.84M | 20.69 | -3.12 | -12.81% | -27.32% | 0.03 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 174.76M | 11.74M | 27.86M | 63.04M | 65.14M | 75.44M | 99.77M | 198.96M | 285.5M |
| Revenue Growth % | - | - | -0.93% | 1.37% | 1.26% | 0.03% | 0.16% | 0.32% | 0.99% | 0.43% |
| Cost of Goods Sold | 140.41M | 50.09M | 17.23M | 20.48M | 27.98M | 24.64M | 38.86M | 57.5M | 62.77M | 76.6M |
| COGS % of Revenue | - | 0.29% | 1.47% | 0.74% | 0.44% | 0.38% | 0.52% | 0.58% | 0.32% | 0.27% |
| Gross Profit | -140.41M | 124.67M | -5.48M | 7.38M | 35.06M | 40.5M | 36.59M | 42.27M | 136.19M | 208.9M |
| Gross Margin % | - | 0.71% | -0.47% | 0.26% | 0.56% | 0.62% | 0.48% | 0.42% | 0.68% | 0.73% |
| Gross Profit Growth % | - | 1.89% | -1.04% | 2.35% | 3.75% | 0.16% | -0.1% | 0.16% | 2.22% | 0.53% |
| Operating Expenses | 204.24M | 59.58M | 88.86M | 88.44M | 79.66M | 88.42M | 83.61M | 106.38M | 127.51M | 136.31M |
| OpEx % of Revenue | - | 0.34% | 7.57% | 3.17% | 1.26% | 1.36% | 1.11% | 1.07% | 0.64% | 0.48% |
| Selling, General & Admin | 108.4M | 46.93M | 74.96M | 79.72M | 74.67M | 59.04M | 77.42M | 91.47M | 94.31M | 94.33M |
| SG&A % of Revenue | - | 0.27% | 6.38% | 2.86% | 1.18% | 0.91% | 1.03% | 0.92% | 0.47% | 0.33% |
| Research & Development | 29.67M | 14.92M | 14.12M | 8.74M | 6.9M | 6.25M | 12.31M | 19.72M | 31.28M | 45.89M |
| R&D % of Revenue | - | 0.09% | 1.2% | 0.31% | 0.11% | 0.1% | 0.16% | 0.2% | 0.16% | 0.16% |
| Other Operating Expenses | 1.37M | -597K | 13K | -437K | -1.91M | 23.13M | -6.12M | -4.81M | 1.92M | -3.91M |
| Operating Income | -344.65M | 67.26M | -108.19M | -76.59M | -44.6M | -47.91M | -47.02M | -64.11M | 8.68M | 72.59M |
| Operating Margin % | - | 0.38% | -9.21% | -2.75% | -0.71% | -0.74% | -0.62% | -0.64% | 0.04% | 0.25% |
| Operating Income Growth % | -0.92% | 1.2% | -2.61% | 0.29% | 0.42% | -0.07% | 0.02% | -0.36% | 1.14% | 7.36% |
| EBITDA | -331.38M | 69.66M | -106.39M | -74.89M | -42.44M | -44.59M | -43.78M | -57.8M | 13.21M | 81.56M |
| EBITDA Margin % | - | 0.4% | -9.06% | -2.69% | -0.67% | -0.68% | -0.58% | -0.58% | 0.07% | 0.29% |
| EBITDA Growth % | -1.06% | 1.21% | -2.53% | 0.3% | 0.43% | -0.05% | 0.02% | -0.32% | 1.23% | 5.17% |
| D&A (Non-Cash Add-back) | 13.28M | 2.4M | 1.8M | 1.7M | 2.15M | 3.33M | 3.24M | 6.31M | 4.54M | 8.97M |
| EBIT | -345.11M | 144.14M | -104.01M | -77.3M | -41M | -47.99M | -64.35M | -62.63M | 10.59M | 68.5M |
| Net Interest Income | -24.11M | -18.39M | -12.98M | -8.94M | -9.91M | -9.3M | -16.46M | -22.26M | -19.01M | -25.37M |
| Interest Income | 18K | 85K | 293K | 501K | 997K | 167K | 112K | 2.51M | 6.15M | 12.62M |
| Interest Expense | 24.13M | 18.48M | 13.28M | 9.44M | 10.91M | 9.47M | 16.58M | 24.77M | 25.16M | 37.98M |
| Other Income/Expense | -23.79M | 58.4M | -9.09M | -10.14M | -7.31M | -9.54M | -33.9M | -23.29M | -19.05M | -42.07M |
| Pretax Income | -368.44M | 125.66M | -117.28M | -86.73M | -51.9M | -57.46M | -80.93M | -87.4M | -10.38M | 30.52M |
| Pretax Margin % | - | 0.72% | -9.99% | -3.11% | -0.82% | -0.88% | -1.07% | -0.88% | -0.05% | 0.11% |
| Income Tax | 0 | 0 | 51K | 240K | 0 | -218K | 0 | 0 | 1.56M | 2.93M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1.15% | 0.9% |
| Net Income | -368.44M | 125.66M | -117.33M | -86.97M | -51.9M | -57.24M | -80.93M | -87.4M | -11.94M | 27.59M |
| Net Margin % | - | 0.72% | -9.99% | -3.12% | -0.82% | -0.88% | -1.07% | -0.88% | -0.06% | 0.1% |
| Net Income Growth % | -0.86% | 1.34% | -1.93% | 0.26% | 0.4% | -0.1% | -0.41% | -0.08% | 0.86% | 3.31% |
| Net Income (Continuing) | -368.44M | 125.66M | -117.33M | -86.97M | -51.9M | -57.24M | -80.93M | -87.4M | -11.94M | 27.59M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.54 | 1.36 | -1.13 | -0.60 | -0.31 | -0.26 | -0.37 | -0.44 | -0.04 | 0.10 |
| EPS Growth % | -0.77% | 1.3% | -1.83% | 0.47% | 0.48% | 0.16% | -0.42% | -0.19% | 0.9% | 3.17% |
| EPS (Basic) | -4.54 | 1.37 | -1.13 | -0.60 | -0.31 | -0.26 | -0.37 | -0.44 | -0.04 | 0.10 |
| Diluted Shares Outstanding | 81.23M | 92.08M | 104.25M | 144.14M | 195.58M | 222.59M | 249.24M | 257.09M | 267.01M | 283.84M |
| Basic Shares Outstanding | 81.16M | 92.05M | 103.83M | 144.14M | 195.58M | 222.59M | 249.24M | 257.09M | 267.01M | 274.42M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 76.65M | 77.49M | 57.22M | 81.85M | 60.76M | 79.48M | 219.49M | 234.9M | 373.39M | 268.31M |
| Cash & Short-Term Investments | 59.07M | 22.89M | 43.95M | 71.16M | 49.88M | 67M | 204.12M | 170.85M | 295.1M | 197.26M |
| Cash Only | 59.07M | 22.89M | 43.95M | 71.16M | 29.91M | 67M | 124.18M | 69.77M | 238.48M | 46.34M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 19.98M | 0 | 79.93M | 101.08M | 56.62M | 150.92M |
| Accounts Receivable | 23K | 30.86M | 2.79M | 4.02M | 3.51M | 4.22M | 4.74M | 16.8M | 14.9M | 11.8M |
| Days Sales Outstanding | - | 64.45 | 86.67 | 52.63 | 20.34 | 23.63 | 22.93 | 61.47 | 27.34 | 15.09 |
| Inventory | 13.54M | 2.33M | 2.66M | 3.6M | 4.16M | 4.97M | 7.15M | 21.77M | 28.55M | 27.89M |
| Days Inventory Outstanding | 35.19 | 16.98 | 56.29 | 64.11 | 54.2 | 73.66 | 67.18 | 138.21 | 165.98 | 132.87 |
| Other Current Assets | 13.54M | 17.04M | 5.21M | 527K | 316K | 158K | 0 | 25.48M | 34.85M | 31.36M |
| Total Non-Current Assets | 49.76M | 29.57M | 27.36M | 25.85M | 32.97M | 29.13M | 101.67M | 60.39M | 101.81M | 125.54M |
| Property, Plant & Equipment | 48.75M | 28.93M | 26.92M | 25.6M | 26.78M | 25.87M | 36.61M | 45.13M | 84.22M | 85.36M |
| Fixed Asset Turnover | - | 6.04x | 0.44x | 1.09x | 2.35x | 2.52x | 2.06x | 2.21x | 2.36x | 3.34x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.43M | 1.93M | 1.93M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.15M | 1.07M | 5.26M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 56.62M | 1.96M | 7.16M | 5.48M |
| Other Non-Current Assets | 1.01M | 648K | 437K | 249K | 6.19M | 3.27M | 8.44M | 9.72M | 7.43M | 27.49M |
| Total Assets | 126.41M | 107.06M | 84.58M | 107.7M | 93.72M | 108.61M | 321.16M | 295.28M | 475.2M | 393.84M |
| Asset Turnover | - | 1.63x | 0.14x | 0.26x | 0.67x | 0.60x | 0.23x | 0.34x | 0.42x | 0.72x |
| Asset Growth % | -0.68% | -0.15% | -0.21% | 0.27% | -0.13% | 0.16% | 1.96% | -0.08% | 0.61% | -0.17% |
| Total Current Liabilities | 268.32M | 92.05M | 87.6M | 75.24M | 65.62M | 73.7M | 48.35M | 67.3M | 104.13M | 81.84M |
| Accounts Payable | 15.6M | 3.26M | 6.98M | 5.38M | 4.79M | 5.58M | 6.96M | 11.05M | 9.58M | 6.79M |
| Days Payables Outstanding | 40.55 | 23.78 | 147.97 | 95.87 | 62.47 | 82.68 | 65.34 | 70.16 | 55.71 | 32.36 |
| Short-Term Debt | 74.58M | 71.34M | 52.74M | 11.3M | 5.03M | 4.06M | 6.98M | 9.56M | 20M | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 827K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 173.96M | 6.45M | 12.97M | 46.76M | 10.13M | 13.46M | 9.53M | 16.43M | 30.97M | 30.37M |
| Current Ratio | 0.29x | 0.84x | 0.65x | 1.09x | 0.93x | 1.08x | 4.54x | 3.49x | 3.59x | 3.28x |
| Quick Ratio | 0.24x | 0.82x | 0.62x | 1.04x | 0.86x | 1.01x | 4.39x | 3.17x | 3.31x | 2.94x |
| Cash Conversion Cycle | - | 57.66 | -5 | 20.87 | 12.07 | 14.61 | 24.77 | 129.52 | 137.61 | 115.6 |
| Total Non-Current Liabilities | 208.42M | 198.6M | 211.71M | 207.55M | 218.63M | 215.32M | 482.16M | 478.52M | 617.24M | 390.82M |
| Long-Term Debt | 139.5M | 77.16M | 104.08M | 91.19M | 113.87M | 118.17M | 281.2M | 273.49M | 248.7M | 36.05M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 2.51M | 1.2M | 1.04M | 5.34M | 3.92M | 11.64M |
| Deferred Tax Liabilities | 0 | 0 | -500K | -10.68M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 68.92M | 121.45M | 107.63M | 105.68M | 93.9M | 94.28M | 175.43M | 162.01M | 294.82M | 291.97M |
| Total Liabilities | 476.75M | 290.66M | 299.31M | 282.79M | 284.25M | 289.03M | 530.51M | 545.82M | 721.37M | 472.66M |
| Total Debt | 139.5M | 148.5M | 156.82M | 102.49M | 121.41M | 123.44M | 289.22M | 288.4M | 272.62M | 47.7M |
| Net Debt | 80.43M | 125.6M | 112.88M | 31.33M | 91.51M | 56.43M | 165.03M | 218.63M | 34.14M | 1.36M |
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | 2.13x | - | - | - | - | - | - | 20.63x | 0.58x |
| Net Debt / EBITDA | - | 1.80x | - | - | - | - | - | - | 2.58x | 0.02x |
| Interest Coverage | -14.29x | 3.64x | -8.15x | -8.11x | -4.09x | -5.06x | -2.84x | -2.59x | 0.34x | 1.91x |
| Total Equity | -350.33M | -183.59M | -214.73M | -175.08M | -190.53M | -180.42M | -209.35M | -250.54M | -246.17M | -78.82M |
| Equity Growth % | -3.75% | 0.48% | -0.17% | 0.18% | -0.09% | 0.05% | -0.16% | -0.2% | 0.02% | 0.68% |
| Book Value per Share | -4.31 | -1.99 | -2.06 | -1.21 | -0.97 | -0.81 | -0.84 | -0.97 | -0.92 | -0.28 |
| Total Shareholders' Equity | -350.33M | -183.59M | -214.73M | -175.08M | -190.53M | -180.42M | -209.35M | -250.54M | -246.17M | -78.82M |
| Common Stock | 4.29M | 4.78M | 1.19M | 1.87M | 2.12M | 2.42M | 2.52M | 2.64M | 2.7M | 3.03M |
| Retained Earnings | -2.86B | -2.74B | -2.85B | -2.94B | -2.99B | -3.05B | -3.13B | -3.22B | -3.23B | -3.2B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -20K | -24K | -18K | -19K | -19K | 0 | 0 | 0 | 0 | 1.11M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -57.23M | -78.09M | -64.78M | -37.73M | -88.48M | -28.13M | -61.71M | -80.7M | 34.09M | 42.51M |
| Operating CF Margin % | - | -0.45% | -5.52% | -1.35% | -1.4% | -0.43% | -0.82% | -0.81% | 0.17% | 0.15% |
| Operating CF Growth % | -15.01% | -0.36% | 0.17% | 0.42% | -1.35% | 0.68% | -1.19% | -0.31% | 1.42% | 0.25% |
| Net Income | -368.44M | 125.66M | -117.33M | -86.97M | -51.9M | -57.24M | -80.93M | -87.4M | -11.94M | 27.59M |
| Depreciation & Amortization | 13.28M | 4.16M | 3.53M | 1.7M | 2.15M | 3.33M | 5.47M | 6.29M | 5.8M | 9.04M |
| Stock-Based Compensation | 8.72M | 5.13M | 4.85M | 6.86M | 6.2M | 6.51M | 12.2M | 0 | 17.65M | 21.36M |
| Deferred Taxes | 180.43M | -79.57M | 12.94M | 0 | -4.57M | 10.65M | 12.64M | 0 | 0 | 0 |
| Other Non-Cash Items | 67.81M | 5.79M | 3.67M | 5.71M | -28M | 18.4M | 6.63M | 24.47M | 7.96M | 21M |
| Working Capital Changes | 40.97M | -139.27M | 27.57M | 36.68M | -12.36M | -9.78M | -17.73M | -24.05M | 14.63M | -36.47M |
| Change in Receivables | 51.58M | -302K | -2.49M | -1.34M | 504K | -705K | -776K | -11.81M | 2.35M | 2.65M |
| Change in Inventory | -26.43M | -2.33M | -3.3M | -3.15M | -558K | -1.31M | -4.08M | -5.67M | 4.57M | -3.2M |
| Change in Payables | 8.41M | -12.12M | 3.8M | -1.6M | -593K | 793K | 1.37M | 4.1M | -1.47M | -2.79M |
| Cash from Investing | -10.2M | -1.13M | 16.68M | -234K | -22.84M | 15.22M | -151.54M | 4.87M | -1.99M | -96.65M |
| Capital Expenditures | -10.29M | -1.14M | 0 | -354K | -2.56M | -4.78M | -11.47M | -7.59M | -42.44M | -9.69M |
| CapEx % of Revenue | - | 0.01% | - | 0.01% | 0.04% | 0.07% | 0.15% | 0.08% | 0.21% | 0.03% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 82K | 17K | 16.68M | 120K | -300K | 20M | 56.06M | 32.8M | 382K | 128.71M |
| Cash from Financing | 5.67M | 43.04M | 73.56M | 61.29M | 69.86M | 49.85M | 270.27M | 21.41M | 136.61M | -137.27M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 1.27M | -2.85M | -120K | -4.22M | 2.97M | 11.31M | -12.7M | -62K | 136.58M | 1.99M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -67.52M | -79.23M | -64.78M | -38.09M | -91.05M | -32.91M | -73.17M | -88.29M | -8.35M | 32.82M |
| FCF Margin % | - | -0.45% | -5.52% | -1.37% | -1.44% | -0.51% | -0.97% | -0.88% | -0.04% | 0.11% |
| FCF Growth % | -2.37% | -0.17% | 0.18% | 0.41% | -1.39% | 0.64% | -1.22% | -0.21% | 0.91% | 4.93% |
| FCF per Share | -0.83 | -0.86 | -0.62 | -0.26 | -0.47 | -0.15 | -0.29 | -0.34 | -0.03 | 0.12 |
| FCF Conversion (FCF/Net Income) | 0.16x | -0.62x | 0.55x | 0.43x | 1.70x | 0.49x | 0.76x | 0.92x | -2.86x | 1.54x |
| Interest Paid | 0 | 0 | 7.73M | 3.76M | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 51K | 240K | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | - | 71.34% | -46.68% | 26.49% | 55.62% | 62.17% | 48.49% | 42.37% | 68.45% | 73.17% |
| Net Margin | - | 71.91% | -999% | -312.2% | -82.34% | -87.87% | -107.27% | -87.6% | -6% | 9.66% |
| Interest Coverage | -14.29x | 3.64x | -8.15x | -8.11x | -4.09x | -5.06x | -2.84x | -2.59x | 0.34x | 1.91x |
| FCF Conversion | 0.16x | -0.62x | 0.55x | 0.43x | 1.70x | 0.49x | 0.76x | 0.92x | -2.86x | 1.54x |
| Revenue Growth | - | - | -93.28% | 137.2% | 126.28% | 3.34% | 15.81% | 32.25% | 99.42% | 43.5% |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Royalty | - | - | - | - | - | - | 15.6M | - | 102.33M |
| Royalty Growth | - | - | - | - | - | - | - | - | - |
| License and Service | - | - | - | - | - | - | - | 41.91M | 100.84M |
| License and Service Growth | - | - | - | - | - | - | - | - | 140.62% |
| Product | - | - | - | - | 32.32M | 39.17M | 56.25M | - | 82.33M |
| Product Growth | - | - | - | - | - | 21.17% | 43.60% | - | - |
| Product Sales | - | - | - | - | - | - | 81.07M | - | - |
| Product Sales Growth | - | - | - | - | - | - | - | - | - |
| Service | - | - | - | - | - | - | 3.1M | - | - |
| Service Growth | - | - | - | - | - | - | - | - | - |
| License And Service | - | - | 1.08M | 7.9M | 9.56M | 22.02M | - | - | - |
| License And Service Growth | - | - | - | 633.61% | 20.96% | 130.45% | - | - | - |
| Bulk Insulin Sales | - | 1.7M | - | - | - | - | - | - | - |
| Bulk Insulin Sales Growth | - | - | - | - | - | - | - | - | - |
| Insulin | 10.2M | - | - | - | - | - | - | - | - |
| Insulin Growth | - | - | - | - | - | - | - | - | - |
MannKind Corporation (MNKD) has a price-to-earnings (P/E) ratio of 58.0x. This suggests investors expect higher future growth.
MannKind Corporation (MNKD) reported $313.8M in revenue for fiscal year 2024. This represents a 627474% increase from $0.1M in 2011.
MannKind Corporation (MNKD) grew revenue by 43.5% over the past year. This is strong growth.
Yes, MannKind Corporation (MNKD) is profitable, generating $29.2M in net income for fiscal year 2024 (9.7% net margin).
MannKind Corporation (MNKD) generated $43.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.